Fig. 1From: Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapySurvival analysis in the brain metastases (BM) and leptomeningeal metastases (LM) cohorts. A Median progression-free survival (PFS) and B intracranial PFS (iPFS) in the BM cohort. C Median PFS and median iPFS (D) in the LM cohortBack to article page